Physician profile
Mark Mahan
NPI 1841730496
$4,895.64
in general payments reported to CMS, 2019-2025
11 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $337 · 2022: $1,527 · 2023: $1,611 · 2024: $1,151 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469 · Travel and Lodging: $1,427 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.68 |
| Travel and Lodging | $1,426.83 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,333.75 | 2022-2024 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $497.79 | 2022 | |
| Ethicon US, LLC | $180.57 | 2021-2024 | Harmonic, Stratafix |
| Boston Scientific Corporation | $150.00 | 2024 | |
| W. L. Gore & Associates, INC. | $149.93 | 2025 | Gore Propaten Vascular Graft |
| Haemonetics Corporation | $120.76 | 2024 | Teg6s Hemostasis System |
| Misonix INC | $119.99 | 2019 | |
| Atricure, INC. | $100.72 | 2021 | |
| Smith+Nephew, INC. | $87.38 | 2021-2024 | Renasys Touch |
| Integra Lifesciences Corporation | $78.40 | 2021-2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Medtronic, INC. | $76.35 | 2024 | Dextile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.